OwnershipPublicly listed · Nasdaq: NTLASEC EDGAR company record and tickers file (Nasdaq: NTLA) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as Nasdaq: NTLA, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.
6developments published
—US federal obligations on record
0federal awards
Sep 8, 2026latest development
Timeline
- Sep 8, 2026 · Company announcement
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Company-reported - Sep 4, 2026 · Financing
Intellia Therapeutics reports entry into a material definitive agreement (Form 8-K, Item 1.01)
Regulatory filing - Aug 6, 2026 · Reported results
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Company-reported - Jun 13, 2026 · Company announcement
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Company-reported - Jun 9, 2026 · Shareholder vote
Intellia Therapeutics reports results of a shareholder vote (Form 8-K, Item 5.07)
Regulatory filing - May 11, 2026 · Reported results
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Company-reported
Profile
- Legal name
- Intellia Therapeutics, Inc.
- Listing
- Nasdaq NTLA
- SEC filer
- CIK 0001652130 ↗
- SEC industry code
- In Vitro & In Vivo Diagnostic Substances
- Incorporated
- DE
- Coverage
- Filings + federal awards
Mix of developments
Watch Intellia Therapeutics
Anything new from Intellia Therapeutics lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digest